Show simple item record

dc.contributor.authorSharma, Samanta
dc.contributor.authorZhang, Tian
dc.contributor.authorMichowski, Wojciech
dc.contributor.authorRebecca, Vito W
dc.contributor.authorXiao, Min
dc.contributor.authorFerretti, Roberta
dc.contributor.authorSuski, Jan M
dc.contributor.authorBronson, Roderick T
dc.contributor.authorPaulo, Joao A
dc.contributor.authorFrederick, Dennie
dc.contributor.authorFassl, Anne
dc.contributor.authorBoland, Genevieve M
dc.contributor.authorGeng, Yan
dc.contributor.authorLees, Jacqueline A
dc.contributor.authorMedema, Rene H
dc.contributor.authorHerlyn, Meenhard
dc.contributor.authorGygi, Steven P
dc.contributor.authorSicinski, Piotr
dc.date.accessioned2021-10-27T20:22:24Z
dc.date.available2021-10-27T20:22:24Z
dc.date.issued2020
dc.identifier.urihttps://hdl.handle.net/1721.1/135192
dc.description.abstract© 2020 National Academy of Sciences. All rights reserved. The cyclin-dependent kinase 5 (CDK5), originally described as a neuronal-specific kinase, is also frequently activated in human cancers. Using conditional CDK5 knockout mice and a mouse model of highly metastatic melanoma, we found that CDK5 is dispensable for the growth of primary tumors. However, we observed that ablation of CDK5 completely abrogated the metastasis, revealing that CDK5 is essential for the metastatic spread. In mouse and human melanoma cells CDK5 promotes cell invasiveness by directly phosphorylating an intermediate filament protein, vimentin, thereby inhibiting assembly of vimentin filaments. Chemical inhibition of CDK5 blocks the metastatic spread of patient-derived melanomas in patient-derived xenograft (PDX) mouse models. Hence, inhibition of CDK5 might represent a very potent therapeutic strategy to impede the metastatic dissemination of malignant cells.
dc.language.isoen
dc.publisherProceedings of the National Academy of Sciences
dc.relation.isversionof10.1073/PNAS.1912617117
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
dc.sourcePNAS
dc.titleTargeting the cyclin-dependent kinase 5 in metastatic melanoma
dc.typeArticle
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MIT
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biology
dc.relation.journalProceedings of the National Academy of Sciences of the United States of America
dc.eprint.versionFinal published version
dc.type.urihttp://purl.org/eprint/type/JournalArticle
eprint.statushttp://purl.org/eprint/status/PeerReviewed
dc.date.updated2021-07-20T18:31:44Z
dspace.orderedauthorsSharma, S; Zhang, T; Michowski, W; Rebecca, VW; Xiao, M; Ferretti, R; Suski, JM; Bronson, RT; Paulo, JA; Frederick, D; Fassl, A; Boland, GM; Geng, Y; Lees, JA; Medema, RH; Herlyn, M; Gygi, SP; Sicinski, P
dspace.date.submission2021-07-20T18:31:46Z
mit.journal.volume117
mit.journal.issue14
mit.licensePUBLISHER_POLICY
mit.metadata.statusAuthority Work and Publication Information Needed


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record